Squarepoint Ops LLC Has $1.96 Million Stock Position in Compass Pathways PLC Sponsored ADR $CMPS

Key Points

• Squarepoint Ops LLC increased its Compass Pathways stake by 751.1% in the second quarter, holding 138,671 shares worth approximately $1.96 million. Institutional investors and hedge funds collectively own 46.19% of the company.
• Compass Pathways shares opened at $14.54, near their 52-week high of $15.87, but the company reported a quarterly loss of $1.88 per share—well below analysts’ expected loss of $0.39.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $23.36. The company is developing COMP360, a psilocybin-based therapy primarily targeting treatment-resistant depression.

Squarepoint Ops LLC grew its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 751.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 138,671 shares of the company's stock after purchasing an additional 122,378 shares during the period. Squarepoint Ops LLC owned approximately 0.10% of Compass Pathways worth $1,962,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Orbimed Advisors LLC acquired a new stake in shares of Compass Pathways during the 1st quarter worth about $6,363,000. Affinity Asset Advisors LLC lifted its holdings in Compass Pathways by 454.2% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company's stock valued at $6,130,000 after purchasing an additional 908,483 shares during the last quarter. NEXTBio Capital Management LP acquired a new position in Compass Pathways in the fourth quarter valued at about $5,193,000. Eversept Partners LP acquired a new position in Compass Pathways in the first quarter valued at about $3,749,000. Finally, Eagle Health Investments LP grew its stake in Compass Pathways by 62.4% during the fourth quarter. Eagle Health Investments LP now owns 1,519,388 shares of the company's stock worth $10,484,000 after buying an additional 583,938 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Stock Up 1.3%

Shares of NASDAQ CMPS opened at $14.54 on Tuesday. Compass Pathways PLC Sponsored ADR has a 1 year low of $4.82 and a 1 year high of $15.87. The firm's 50-day moving average is $13.16 and its 200-day moving average is $10.63. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $2.01 billion, a PE ratio of -3.15 and a beta of 2.54.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($1.49). Equities analysts expect that Compass Pathways PLC Sponsored ADR will post -1.26 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Oppenheimer reaffirmed an "outperform" rating on shares of Compass Pathways in a report on Wednesday, August 5th. Raymond James Financial reissued a "buy" rating on shares of Compass Pathways in a report on Friday, May 22nd. Wall Street Zen upgraded Compass Pathways from a "strong sell" rating to a "sell" rating in a research report on Tuesday, September 1st. Jefferies Financial Group reaffirmed a "buy" rating on shares of Compass Pathways in a report on Wednesday, September 9th. Finally, Wolfe Research reaffirmed an "outperform" rating on shares of Compass Pathways in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.36.

Compass Pathways Profile

Compass Pathways plc NASDAQ: CMPS is a biotechnology company developing novel treatments for mental health conditions. The company's primary focus is psilocybin therapy, which combines a proprietary investigational formulation with psychological support delivered by trained therapists.

Its lead candidate, COMP360, is a synthetic crystalline formulation of psilocybin being studied primarily for treatment-resistant depression. Compass Pathways has conducted mid- and late-stage clinical trials evaluating COMP360 and has also investigated its potential use in other difficult-to-treat psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.